Latest news
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight - BioSpaceBioSpace · Thu, 06 Aug 2026 22:18:12 GMTFive BioSpace NextGen Companies Account for One-Third of 2026 Biotech IPOs - geneonline.comgeneonline.com · Wed, 05 Aug 2026 12:18:30 GMTTwist Bioscience Announces Fiscal 2026 Third Quarter Financial Results - BioSpaceBioSpace · Tue, 04 Aug 2026 02:30:53 GMTNovo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9% - BioSpaceBioSpace · Fri, 31 Jul 2026 15:27:37 GMTModerna maintains 10% growth target despite Phase 3 norovirus miss - BioSpaceBioSpace · Fri, 31 Jul 2026 07:00:00 GMTUPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMTArgenx deepens immuno expertise with $2.2B Forte Biosciences buy - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMT